Literature DB >> 25991470

Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.

Jean L Mbisa1, Esther Fearnhill2, David T Dunn2, Deenan Pillay3, David Asboe4, Patricia A Cane1.   

Abstract

BACKGROUND: About 10% of new diagnoses of subtype B human immunodeficiency virus type 1 (HIV-1) in the United Kingdom are with viruses showing transmitted drug resistance (TDR). However, there is discordance between the mutation patterns observed in HIV-infected patients failing therapy and those seen in TDR.
METHODS: We extracted all subtype B HIV-1 pol gene sequences from treatment-naive patients within the United Kingdom HIV Drug Resistance Database sampled between 1997 and 2011 and carrying the most common protease inhibitors, nonnucleoside and nucleotide reverse transcriptase inhibitors TDR mutations, namely, L90M, K103N, and T215Y/F/rev, respectively (n = 1140). Transmission clusters (n ≥ 2 sequences) were identified by maximum-likelihood phylogeny using a genetic distance cutoff of ≤ 1.5%. The time of origin and the basic reproductive number (R0) of clusters were estimated by Bayesian methods.
RESULTS: T215rev was present alone in 47% of the sequences (n = 540), K103N in 31% (n = 359), and L90M in 10% (n = 109). The remaining sequences contained T215Y or combinations of L90M, K103N, and T215rev. Fifty-five percent (n = 624) of the sequences formed highly supported transmission clusters (n = 193) containing between 2 and 15 sequences. The time of origin of 10 large clusters (≥ 8 sequences) was estimated to be between 2000 (1999-2002; 95% highest posterior density [HPD]) and 2006 (2005-2007; 95% HPD). The oldest cluster had persisted for nearly 8 years. All 10 clusters had R0s ranging from 1.3 (0.4-2.5; 95% HPD) to 2.8 (0.6-6.5; 95% HPD).
CONCLUSIONS: A high proportion of the most common TDR in subtype B infections in the United Kingdom is derived by onward transmission from treatment-naive patients. © Crown copyright 2015.

Entities:  

Keywords:  HIV-1–transmitted drug resistance; subtype B; treatment-naive patients

Mesh:

Year:  2015        PMID: 25991470     DOI: 10.1093/cid/civ393

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013.

Authors:  A Zoufaly; C Kraft; C Schmidbauer; E Puchhammer-Stoeckl
Journal:  Infection       Date:  2016-08-16       Impact factor: 3.553

2.  Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation.

Authors:  Kenny Dauwe; Delfien Staelens; Leen Vancoillie; Virginie Mortier; Chris Verhofstede
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948

3.  Integration of Contact Tracing and Phylogenetics in an Investigation of Acute HIV Infection.

Authors:  Ann M Dennis; Dana K Pasquale; Rachael Billock; Steve Beagle; Victoria Mobley; Anna Cope; JoAnn Kuruc; Joseph Sebastian; Charles Walworth; Peter A Leone
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 2.830

4.  Editorial Commentary: The Irreversibility of HIV Drug Resistance.

Authors:  Roger D Kouyos; Huldrych F Günthard
Journal:  Clin Infect Dis       Date:  2015-05-19       Impact factor: 9.079

5.  Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.

Authors:  A Tostevin; E White; D Dunn; S Croxford; V Delpech; I Williams; D Asboe; A Pozniak; D Churchill; A M Geretti; D Pillay; C Sabin; A Leigh-Brown; E Smit
Journal:  HIV Med       Date:  2016-08-01       Impact factor: 3.180

6.  Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health.

Authors:  Dimitrios Paraskevis; Evangelia Kostaki; Panagiotis Gargalianos; Georgios Xylomenos; Marios Lazanas; Maria Chini; Athanasios Skoutelis; Vasileios Papastamopoulos; Dimitra Paraskeva; Anastasia Antoniadou; Antonios Papadopoulos; Mina Psichogiou; Georgios L Daikos; Georgios Chrysos; Vasileios Paparizos; Sofia Kourkounti; Helen Sambatakou; Nikolaos V Sipsas; Malvina Lada; Periklis Panagopoulos; Efstratios Maltezos; Stylianos Drimis; Angelos Hatzakis
Journal:  Genes (Basel)       Date:  2017-11-13       Impact factor: 4.096

7.  National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014.

Authors:  Andrea Hauser; Alexandra Hofmann; Kirsten Hanke; Viviane Bremer; Barbara Bartmeyer; Claudia Kuecherer; Norbert Bannert
Journal:  Euro Surveill       Date:  2017-01-12

8.  Drug resistant HIV: Behaviors and characteristics among Los Angeles men who have sex with men with new HIV diagnosis.

Authors:  Pamina M Gorbach; Marjan Javanbakht; Lorelei Bornfleth; Robert K Bolan; Martha Lewis Blum
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

9.  Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.

Authors:  Denise Kühnert; Roger Kouyos; George Shirreff; Jūlija Pečerska; Alexandra U Scherrer; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Huldrych F Günthard; Tanja Stadler; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2018-02-20       Impact factor: 6.823

10.  Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.

Authors:  Andrea Hauser; Alexandra Hofmann; Karolin Meixenberger; Britta Altmann; Kirsten Hanke; Viviane Bremer; Barbara Bartmeyer; Norbert Bannert
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.